News
By the numbers To measure the prevalence of options opportunism, BI obtained data for every CEO options grant from companies in the S&P 500 from 2012 through 2023, collected by the executive ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results